1、Hellstr?m A, Smith LE, Dammann O, et al. Retinopathy of prematurity[J].
Lancet, 2013, 382(9902): 1445-1457.Hellstr?m A, Smith LE, Dammann O, et al. Retinopathy of prematurity[J].
Lancet, 2013, 382(9902): 1445-1457.
2、彭立, 谢青, 陈敏华. 抗VEGF治疗在眼科的临床意义及研究进
展[ J]. 国际眼科杂志, 2020, 20(2): 282-285.
PENG Li, XIE Qing, CHEN Minhua. Clinical significance and recent
research advances of anti-VEGF treatment in ophthalmology[ J].
International Eye Science, 2020, 20(2): 282-285.彭立, 谢青, 陈敏华. 抗VEGF治疗在眼科的临床意义及研究进
展[ J]. 国际眼科杂志, 2020, 20(2): 282-285.
PENG Li, XIE Qing, CHEN Minhua. Clinical significance and recent
research advances of anti-VEGF treatment in ophthalmology[ J].
International Eye Science, 2020, 20(2): 282-285.
3、Gunay M, Sukgen EA, Celik G, et al. Comparison of bevacizumab,
ranibizumab, and laser photocoagulation in the treatment of
retinopathy of prematurity in Turkey[ J]. Curr Eye Res, 2017, 42(3):
462-469.Gunay M, Sukgen EA, Celik G, et al. Comparison of bevacizumab,
ranibizumab, and laser photocoagulation in the treatment of
retinopathy of prematurity in Turkey[ J]. Curr Eye Res, 2017, 42(3):
462-469.
4、Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after
intravitreal bevacizumab versus laser photocoagulation for retinopathy
of prematurity: a 5-year retrospective analysis[ J]. Ophthalmology,
2015, 122(5): 1008-1015.Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after
intravitreal bevacizumab versus laser photocoagulation for retinopathy
of prematurity: a 5-year retrospective analysis[ J]. Ophthalmology,
2015, 122(5): 1008-1015.
5、Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors
for aggressive posterior retinopathy of prematurity following initial
treatment with intravitreal ranibizumab[ J]. BMC Ophthalmol, 2018,
18(1): 150.Tong Q, Yin H, Zhao M, et al. Outcomes and prognostic factors
for aggressive posterior retinopathy of prematurity following initial
treatment with intravitreal ranibizumab[ J]. BMC Ophthalmol, 2018,
18(1): 150.
6、Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monotherapy
for type-1 prethreshold, threshold, and aggressive posterior retinopathy
of prematurity—27 month follow-up results from Turkey[ J]. Graefes
Arch Clin Exp Ophthalmol, 2015, 253(10): 1677-1683.Yetik H, Gunay M, Sirop S, et al. Intravitreal bevacizumab monotherapy
for type-1 prethreshold, threshold, and aggressive posterior retinopathy
of prematurity—27 month follow-up results from Turkey[ J]. Graefes
Arch Clin Exp Ophthalmol, 2015, 253(10): 1677-1683.
7、Zepeda-Romero LC, Liera-Garcia JA, Gutiérrez-Padilla JA, et al.
Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for
retinopathy of prematurity[ J]. Eye (Lond), 2010, 24(5): 931-933.Zepeda-Romero LC, Liera-Garcia JA, Gutiérrez-Padilla JA, et al.
Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for
retinopathy of prematurity[ J]. Eye (Lond), 2010, 24(5): 931-933.
8、Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab
for retinopathy of prematurity in China[ J]. Ophthalmology, 2017,
124(3): 408-409.Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab
for retinopathy of prematurity in China[ J]. Ophthalmology, 2017,
124(3): 408-409.
9、姜燕荣. 关注早产儿视网膜病变抗血管内皮生长因子药物治疗
的结局和终点[ J]. 中华眼底病杂志, 2019, 35(2): 115-118.
JIANG YR. Pay attention to the outcome and the end point of
anti-vascular endothelial growth factor therapy for retinopathy of
prematurity[ J]. Chinese Journal of Ocular Fundus Diseases, 2019,
35(2): 115-118.姜燕荣. 关注早产儿视网膜病变抗血管内皮生长因子药物治疗
的结局和终点[ J]. 中华眼底病杂志, 2019, 35(2): 115-118.
JIANG YR. Pay attention to the outcome and the end point of
anti-vascular endothelial growth factor therapy for retinopathy of
prematurity[ J]. Chinese Journal of Ocular Fundus Diseases, 2019,
35(2): 115-118.
10、梁建宏, 程湧. 谨慎开展抗血管内皮生长因子药物治疗早产儿
视网膜病变[ J]. 中华眼科杂志, 2019, 55(4): 246-249.
LIANG JH, CHENG Y. Be cautious to treat retinopathy
of prematurity w ith anti-vascular endothelial grow th factor
pharmacotherapy[ J]. Chinese Journal of Ophthalmology, 2019, 55(4):
246-249.梁建宏, 程湧. 谨慎开展抗血管内皮生长因子药物治疗早产儿
视网膜病变[ J]. 中华眼科杂志, 2019, 55(4): 246-249.
LIANG JH, CHENG Y. Be cautious to treat retinopathy
of prematurity w ith anti-vascular endothelial grow th factor
pharmacotherapy[ J]. Chinese Journal of Ophthalmology, 2019, 55(4):
246-249.
11、Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for
retinopathy of prematurity[ J]. Curr Opin Pediatr, 2009, 21(2): 182-187.Mintz-Hittner HA, Best LM. Antivascular endothelial growth factor for
retinopathy of prematurity[ J]. Curr Opin Pediatr, 2009, 21(2): 182-187.
12、Ittiara S, Blair MP, Shapiro MJ, et al. Exudative retinopathy and
detachment: A late reactivation of retinopathy of prematurity after
intravitreal bevacizumab[ J]. J AAPOS, 2013, 17(3): 323-325.Ittiara S, Blair MP, Shapiro MJ, et al. Exudative retinopathy and
detachment: A late reactivation of retinopathy of prematurity after
intravitreal bevacizumab[ J]. J AAPOS, 2013, 17(3): 323-325.
13、Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al. Efficacy of
intravitreal bevacizumab for zone-II retinopathy of prematurity[ J].
Acta Ophthalmol, 2016, 94(6): e417-e420.Karkhaneh R, Khodabande A, Riazi-Eafahani M, et al. Efficacy of
intravitreal bevacizumab for zone-II retinopathy of prematurity[ J].
Acta Ophthalmol, 2016, 94(6): e417-e420.
14、Harper CA 3rd, Wright LM, Young RC, et al. Fluorescein angiographic
evaluation of peripheral retinal vasculature after primary intravitreal
ranibizumab for retinopathy of prematurity[ J]. Retina, 2019, 39(4):
700-705.Harper CA 3rd, Wright LM, Young RC, et al. Fluorescein angiographic
evaluation of peripheral retinal vasculature after primary intravitreal
ranibizumab for retinopathy of prematurity[ J]. Retina, 2019, 39(4):
700-705.
15、Martinez-Castellanos MA, Velez-Montoya R, Price K, et al. Vascular
changes on fluorescein angiography of premature infants with low
risk of retinopathy of prematurity after high oxygen exposure[ J]. Int J
Retina Vitreous, 2017, 3: 2.Martinez-Castellanos MA, Velez-Montoya R, Price K, et al. Vascular
changes on fluorescein angiography of premature infants with low
risk of retinopathy of prematurity after high oxygen exposure[ J]. Int J
Retina Vitreous, 2017, 3: 2.
